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SUMMARY
Eighty-six cases of poliomyelitis, 69 paralytic, have been 
reported through the week ended September 19, 1964; less than one- 
third the number of total and paralytic cases reported during the 
corresponding period in 1963; the previous record low year.
A brief description of the 56 paralytic cases, for which indi­
vidual poliomyelitis surveillance case records have been received, 
is included in Section II.
The supplement to this PSU Report includes the report of 
the Surgeon General's Advisory Committee on Oral polio vaccine.
This committee has reviewed the 87 cases of paralytic disease asso­
ciated with oral polio vaccine occurring in non-epidemic areas since 
licensure. A minority report issued by Dr. Albert B. Sabin is also 
included in the supplement along with an epidemiologic summary of the 
problem and a listing of the associated cases studied.
I. CURRENT POLIOMYELITIS MORBIDITY TRENDS
Eighty-six cases of poliomyelitis, 69 paralytic,have been 
reported through the week ending September 19, 1964 (See Table 1). 
These totals represent less than one-third the number of total and 
paralytic cases reported during the corresponding period in 1963 
as shown below:
Poliomyelitis (Cumulated Weekly) Through 38th Week for Five Years
1964 1963 1962 1961 1960
Paralytic 69 235 439 557 1446
Total 86 276 565 849 2111
-2-
The low incidence of poliomyelitis during 1964 is even more 
impressive when the current reporting during the past six weeks is 
compared to previous years (See Figure 1 on page 8):
Six-Week Totals (33rd thru 38th Week) for Five Years
1964 1963 1962 1961 1960
Paralytic 13 103 164 283 669
Total 19 117 201 436 1037
There have been no outbreaks reported thus far in 1964. The 
only states that have reported more than 5 paralytic cases are New 
York (9) and Florida (8).
II. ROUTINE POLIOMYELITIS SURVEILLANCE - 1964
The Polio Surveillance Unit has received individual surveillance 
case records for 56 of the 69 paralytic cases reported through September 
19, 1964. The 56 cases are shown below by age and sex. Seventy-seven 
percent of the cases have been males.









10-14 2 2 4
15-19 5 0 5
20-29 2 1 3
30-39 4 1 5
40+ 8 1 9
Total 43 13 56
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Twenty of the 56 cases have occurred within 30 days follow­
ing ingestion of oral poliomyelitis vaccine (See Special Report in 
Supplement to this PSU Report). A line listing of these 20 cases 
is shown on pages 4 and 5. Fifteen of the 20 vaccine associated 
cases are 15 years of age or older. Nine of the 20 cases followed 
Type III oral polio vaccine, 6 followed trivalent, 3 followed Type I 
and 2 followed Type II vaccine.
1964 Paralytic Poliomyelitis Cases 
Occurring Within 30 Days After OPV










Ala. Escambia 18 M 1-26 0 - - 21 - Ill 3
Ala. Escambia 28 M 3-28 0 - - 20 - III
Colo. Pueblo 5 mos. F 2-4 0 - 23 - - II 1
Fla. ** 25 M 1-31 Unk. - - 12 - III 1
*Fla. Dade 4 mos. F 4-29 0 - - - 13 I 4
Ga. Bartow 15 M 3-5 5 25 - - - Neg. 3
111. Adams 3 mos. M 1-28 Unk. - - 11 - Ill
Md. Pr. Georges 15 M 5-9 0 20 - - - I 4
*Mo. Dunklin 37 F 3-24 0 29 - 2 - Neg.
Nebr. Lancaster 41 M 3-14 Unk. 2yrs.2yrs.5 - - 3
N.J. Mercer 35 M 2-1 0 48 - 13 - Neg. 3
N.J. Morris 41 F 3-23 4 63 - 22 - Neg. 2
N.Y. Nassau 37 M 4-27 0 - - - 8 II 2
N.Y. Fulton 5 M 6-29 3 - - - 11 I, II, III 1
N.C. Alamance 43 M 3-16 0 - - - 15 I 5
N.C. Forsyth 43 M 3-9 0 • • - 8 II 4
State County Age Sex Onset
N.C. Mecklenburg 48 M 4-7
N.C. Lenoir 49 M 6-14
Ohio Lucas 8 mos. M 4-6




OPV to Onset 





0 - - 16 Ill 3
0 84 28 56 - 4
0 38 - 13 Ill 3
Unk. 60 18 2
* Cases reported after Surgeon General's Committee meeting of July 17-18, 1964.
** Reported by Florida State Department of Health as a Florida case. Case received vaccine 
in Duval County, Florida but resides in Kingsland, Georgia.
*** Clinical Status at 60 Days:
1 - Complete Recovery
2 - Minor Involvement
3 - Significant disability




TREND OF 1964 POLIOMYELITIS INCIDENCE
State Cumula- 
and tive






Region 1964 8/15 8/22 8/29 9/5 9/'12 9/19 Total 1963 1962 1961
UNITED STATES
Paralytic 69 1 3 2 1 2 4 13 103 164 283
Nonparalytic 10 - 1 - 1 - - 2 10 28 109
Unspecified 7 - - - 1 2 1 4 4 9 44
Total 86 1 4 2 3 4 5 19 117 201 436
NEW ENGLAND
Paralytic 2 - - - - 1 - 1 2 - 12
Total 2 - - - - 1 - 1 2 - 16
Maine - - - - - - - - - - 2
New Hampshire - - - m - - - - - - 1
Vermont - - - - - - - - 1 - 3
Massachusetts - - - - - - - - 1 - 8
Rhode Island - - - - - - - - - - -
Connecticut 2 - - - - 1 - 1 “ - 2
MIDDLE ATLANTIC
Paralytic 11 - 1 - - - - 1 44 16 n o
Total 12 - 2 - - - - 2 53 20 173
New York 10 - 2 - - - - 2 - 9 138
New Jersey 2 - - - - - - - - 3 16
Pennsylvania - - • - • • • 53 8 19
EAST NORTH CENTRAL
Paralytic 13 - 1 1 1 - 1 4 11 21 34
Total 18 - 1 1 2 2 2 8 13 28 55
Ohio 2 - - - - - - - 1 8 11
Indiana 6 - 1 - - 2 2 5 - 4 6
Illinois 5 - - - - - - - 3 12 9
Michigan 3 - - 1 1 - - 2 6 2 15
Wisconsin 2 - - - 1 • ** 1 3 2 14
WEST NORTH CENTRAL
Paralytic 6 - - 1 - 1 1 3 - 9 13
Total 7 - - 1 - 1 1 3 - 12 27
Minnesota 2 - - - - 1 - 1 - 3 3
Iowa - - - - - - - - - - 13
Missouri 3 - - 1 - - - 1 - 2 4
North Dakota 1 - - - - - 1 1 - 1 1
South Dakota - - - - - - - - - 1 1

















Region 1964 8/15 8/22 8/29 9/5 9/12 9/19 Total 1963 1962 1961
SOUTH ATLANTIC
Paralytic 19 - 1 - - - 1 2 16 18 42
Total 24 - 1 - - m 1 2 16 19 59
Delaware - - - - - - • - 1 - -
Maryland 1 - - - m - - - - - 11
D.C. - - - - - - - - - 1 -
Virginia - - - - - - - - 4 2 6
West Virginia 1 - - - - - - - - 2 10
North Carolina 10 - - - - - 1 1 - 3 7
South Carolina 2 - - - - - - - 1 4 7
Georgia 1 - - - - - - - 9 6 5
Florida 9 - 1 - - - - 1 1 1 13
EAST SOUTH CENTRAL
Paralytic 5 - - - - - 1 1 26 26 21
Total 6 - - - - - 1 1 28 32 30
Kentucky - - - - - - - - - 12 3
Tennessee 3 m - - - - - - 5 5 10
Alabama 2 - - - - - - - 20 14 4
Mississippi 1 - - - - 1 1 3 1 13
WEST SOUTH CENTRAL
Paralytic 6 1 - - - - - 1 2 53 23
Total 7 1 - - 1 - - 2 3 67 42
Arkansas - - - - - - - - 1 4 13
Louisiana - - - - - - - - - 8 13
Oklahoma 2 - - - - - - - - 8 1
Texas S 1 - - 1 - - 2 2 47 15
MOUNTAIN
Paralytic 4 - - - - - - - - - 3
Total 7 - - - - - - - - 2 6
Montana 1 - - - - - - - - - -
Idaho - - - - - - - - - 1 3
Wyoming 2 a - - - - - - - 1 -
Colorado 1 - - - - - - - - - 2
New Mexico 3 - - - - - - - - - -
Arizona - - - - - - - - - - -
Utah - - - - - - - - - - 1
Nevada - - - - - - - - - - -
PACIFIC
Paralytic 3 - - - - - - - 2 21 25
Total 3 m m - - - - - 2 21 28
Washington - - m - - - - - 1 2 7
Oregon 1 - - - - - - - - - 3
California 2 - - - - - - - 1 19 17
Alaska - - - - - - - - - - -
Hawaii m " • • • • • • • 1
















CURRENT INCIDENCE OF PARALYTIC POLIOMYELITIS
BY WEEK OF REPORT -  UNITED STATES
(COMPARED WITH SELECTED YEARS)
tf»RU_ MAY JUNE JUCY AUGUST SEPTEMBER OCTOBER NOVEMBER DECEMBER
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U. S. DEPARTMENT OF 
HEALTH, EDUCATION, AND WELFARE 
Public Health Service 
Washington 25, D. C.
FOR IMMEDIATE RELEASE HEW-C60
Wednesday, September 23, 1964
A special advisory committee to the Surgeon General of the 
Public Health Service, Department of Health, Education, and Welfare, 
urged today renewed drives by local communities during the fall and winter 
to vaccinate the younger age group against poliomyelitis.
The report was prepared by a special advisory committee on oral 
poliomyelitis vaccine and was made public today by Surgeon General Luther 
L. Terry.
The committee's report said that the age group to be immunized 
and the vaccine chosen for use should be determined locally. The committee 
said, however, that in its view the oral vaccination of persons over 18 
should "generally be recommended only in those situations in which unusual 
exposure to poliomyelitis might be anticipated, such as epidemics, entry 
into military service, and travel to other countries."
The committee recommended strongly the immunization of infants 
during their first year of life and the routine immunization of all children 
on entering school.
Dr. Terry, in releasing the report, said that the Public Health 
Service was accepting the committee's reconmendations. He pointed out 
that the shift in emphasis away from adults toward the younger age groups 
was forecast in a committee report of December 1962. The advisory 
committee at that time emphasized the importance of concentrating on the
(more)
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immunization of the younger age groups and noted a "very small risk"
Incident to the use of oral vaccine In persons 30 years of age and over.
The current committee report also recommends alteration In the 
sequence of administering monovalent vaccines, with Type II the first to 
be given. The newly-recommended order Is Type II, I, and III.
Dr. Albert Sabin, developer of the oral vaccine and a member of 
the committee, filed a report dissenting from the committee's recommendations 
and calling for the continued Immunization of all age groups.
The Service Is making available the full text of both reports to 
State Health Officers, professional organizations, and other interested 
agencies, Dr. Terry said.
The committee's recommendations were based on an exhaustive 
analysis of 87 reported cases of "polio-like illness associated with the 
administration of oral vaccines" which have occurred In non-epidemic areas 
since December 1961.
These cases were considered by the committee on the basis of 
whether or not they were "compatible with the possibility of having been 
Induced by the vaccine."
It concluded that it is not possible to prove that any Individual 
case was caused by the vaccines and that no laboratory tests available 
can provide a definitive answer. Nevertheless, the committee said, 
"Considering the epidemiological evidence developed with respect to the 
total group of 'compatible' cases, the committee believes that at least 
some of these cases were caused by the vaccine,"
(more)
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The extent of the "risk factor", according to the report, is, 
for Type III, only 1 case in 2.5 million doses administered; for Type I, 
only 1 in 6 million; and for Type II, only 1 in 50 million.
With respect to the very minimal risk, Dr. Terry emphasized that 
there should be no apprehension whatsoever among those who have already 
taken the oral vaccine.
In its analysis of the 87 cases, the committee found 57 which 
they considered "compatible."
The "compatible" cases, the report said, occurred largely among 
adults. Most were widely scattered throughout the country. The
onset of illness fell between 4 and 28 days following vaccine administration.
"There was no apparent association of cases with specific lots 
of vaccine or vaccines produced by a particular manufacturer," the report 
added.
In urging a renewed effort to vaccinate those still susceptible, 
most of them poorly-immunized children in economically-depressed population 
groups, the committee cited the spectacular decline of polio during recent 
years.
The decline has been from an annual rate of 14.6 cases per 
100,000 during 1950-54 to a rate of 1.8 for 1957-61. This represents a 
decrease of 88 percent.
"On the basis of reports to date, less than 150 cases of paralytic 
poliomyelitis may be anticipated for the entire year (of 1964)," the 
report added.
In commenting on this phase of the report, Surgeon General 
Terry said:
"When you compare this year's record low with the 54,000
(more)
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cases of polio reported in 1952, the triumph against polio is an historic 
achievement in preventive medicine. This great victory has been made 
possible by the work of two extraordinarily dedicated scientists--Dr. Jonas 
Salk and Dr. Albert Sabin--and it has come to pass through the devoted 
efforts of hundreds of organizations and thousands of individuals," Dr. Terry said* 
The Surgeon General added: "I heartily and enthusiastically
endorse the committee's primary recommendation that every effort be made 
for the continuing vaccination of infants and younger age groups. Only 
through this means can we achieve total victory over polio."
Dr. Terry praised the committee for a "painstaking, conscientious 
and thorough report in the public interest."
Members of the Committee were:
Dr. Ernest A. Ager, State Department of Health, Olympia, Washington
Dr. David Bodian, The Johns Hopkins University, Baltimore, Maryland
Dr. Gordon C. Brown, University of Michigan School of Public Health,
Ann Arbor
Dr. Alice D. Chenoweth, Childrens Bureau, Washington, D.C.
Dr. Geoffrey Edsall, Massachusetts Department of Public Health, Boston
Dr. John P. Fox, Public Health Research Institute of Hew York, New York
Dr. James L. Goddard, Communicable Disease Center, Public Health 
Service, Atlanta, Georgia
Dr. A. L. Gray, Mississippi State Board of Health, Jackson
Dr. William McD. Hammon, University of Pittsburgh, Pa.
Dr. Donald A. Henderson, Communicable Disease Center, Public Health 
Service, Atlanta, Georgia
Dr. David T. Karzon, Childrens Hospital, University of Buffalo,
New York, (unable to attend)
(more)
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Dr. Alexander D. Langmuir, Communicable Disease Center, Public 
Health Service, Atlanta, Georgia
Dr. Theodore A. Montgomery, California State Department of 
Public Health, Berkeley
Dr. Roderick Murray, National Institutes of Health, Public Health 
Service, Bethesda, Maryland
Dr. Albert Sabin, The Childrens Hospital Research Foundation, 
Cincinnati, Ohio
Dr. Edward B. Shaw, University of California School of Medicine, 
San Francisco
Dr. Paul F. Wehrle, University of Southern California School of 
Medicine, Los Angeles
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Report of a Special Advisory Committee 
on Oral Poliomyelitis Vaccine to the 
Surgeon General of the Public Health Service 
July 17-18, 1964
A special advisory committee on oral poliomyelitis vaccines met 
at the Communicable Disease Center in Atlanta on July 17-18. The group 
consisted of the recently formed Public Health Service Advisory Committee 
on Immunization Practices and members of the Special Oral Poliomyelitis 
Vaccine Advisory Committee that met during 1962. The Surgeon General 
served as Chairman of the group; a list of the members is attached.
The Committee reviewed data regarding the surveillance of polio­
myelitis in this country from 1955-1961 when inactivated poliomyelitis 
vaccines were used and from 1961 to date when oral poliomyelitis vaccines 
have come into use with increasing frequency. Particular attention was 
directed to reported cases of paralytic disease occurring in association 
with the administration of oral vaccines. Recommendations were developed 
for the continuing use of monovalent and trivalent oral poliomyelitis 
vaccines.
Surveillance
The incidence of paralytic poliomyelitis declined from an annual 
level of 14.6 cases per 100,000 in the 5-year period 1950-1954 to a rate 
of approximately 1.8 for the period 1957-1961. This constituted a decrease 
of 88 percent which can be attributed in large measure to the use of 
inactivated poliomyelitis vaccine. Since 1961 the incidence has further 
declined; the paralytic case rate for 1963 was 0.2. A further decrease
2
in cases has been observed during the first 6 months of 1964. On the 
basis of reports to date, less than 150 cases of paralytic poliomyelitis 
may be anticipated for the entire year. Epidemics of poliomyelitis have 
become rare. The comparatively few which occurred in 1963 were numerically 
small and confined largely to poorly immunized preschool children in 
economically depressed population groups.
Utilization of Poliomyelitis Vaccines
From 1955 through 1961, 400 million doses of inactivated poliomyelitis 
vaccine were distributed in the United States. A high proportion of the 
children and more than half of the adults in the population received one 
or more injections of the vaccine. Inactivated vaccine has continued to 
be used in routine pediatric practice and public health immunization 
clinics. In 1962, 36 million doses were distributed and, in 1963, the 
amount declined to 19 million doses.
Since 1961 approximately 100 million doses of each of the three 
types of oral poliomyelitis vaccine have been distributed. These 
vaccines have been used largely in community-wide immunization programs 
and for epidemic control purposes. They also have been employed to an 
increasing extent in routine pediatric immunization practice.
Trivalent oral poliomyelitis vaccine, available since June, 1963, 
has been used primarily in routine immunization and recently in a few 
community-wide programs.
Vaccine Associated Cases
During 1962, the Special Advisory Committee met on a number of 
occasions and reviewed in detail all reported cases of polio-like illness
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associated with the administration of oral vaccines. Eighteen cases of 
paralytic disease were considered by the Committee to be "compatible with 
the possibility of having been induced by the vaccine." Of these, 11 
followed Type III vaccine and 7 came after Type I vaccine. Most of the 
cases occurred in adults. The "maximum potential risk" was stated to be 
"of the order of one per million or less over-all, but higher for those 
over 30 years of age." The Committee at that time recommended that 
community programs of immunization be continued but that "in adults
especially above the age of 30, vaccination should be used --  only with
the full recognition of its very small risk."
Since December 1962, a number of additional reports have been received 
of paralytic poliomyelitis cases which occurred within 30 days after 
receiving oral poliomyelitis vaccines. At the July 17-18, 1954 meeting, 
the Committee considered in detail the 87 such cases reported from non­
epidemic areas since oral vaccines became available.* The clinical, 
laboratory and epidemiological data pertaining to each of these cases 
were carefully reviewed. Those cases meeting the criteria listed below 
were placed in a category termed "compatible" with vaccine association:
1. An onset of illness between 4 and 30 days following feeding 
of the specific vaccine in question and with an onset of 
paralysis not sooner than 6 days after the feeding.
2. Significant residual lower motor neuron paralysis.
* This total of 87 includes both the cases considered in 1962 on which 
additional information has become available and all newly reported 
cases.
3. Laboratory data not inconsistent with respect to multiplication 
of the vaccine virus fed.
4. Mo evidence of: (a) upper motor neuron disease, (b) definite
sensory loss, or (c) progression or recurrence of paralytic 
illness one month or more after onset.
Of the 37 cases considered, 57 were judged "compatible", 21 were 
excluded after careful consideration. In the case of 9, the data were 
insufficient upon which to make a judgment.
Of the 57 cases considered "compatible", 15 followed Type I vaccine,
2 followed Type II, 36 followed Type III and 4 followed trivalent vaccine 
administration.*
These "compatible" cases occurred largely among adults, 44 being 15 
years of age and older, 8 over 50 years. In the group were 46 male and 
11 female cases; 35 had received no inactivated vaccine; 14 had received
3 or more doses. The cases were widely scattered throughout the country 
except for 3 Type III "compatible" cases in different areas in Nebraska,
5 Type I associated cases in Northern California, and 3 trivalent vaccine 
associated cases, all in adults, in North Carolina. The onsets of ill­
ness of the cases fell between 4 and 28 days with the majority occurring 
within 8 to 21 days following vaccine administration. There was no 
apparent association of cases with specific lots of vaccine or vaccines 
produced by a particular manufacturer.
*Employing the point binomial it is possible to make an approximate 
test of statistical significance of these findings. Assuming inde­
pendence of risk and recognizing that essentially equal amounts of 
oral vaccine of each type were distributed the probability that 2 
Type II cases and 15 Type I cases could have occurred by chance 
alone is 2.4 in a thousand (P=0.0024); the probability of 2 Type II 
cases and 36 Type III cases is one in 185 million (P=0.000000005).
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Evaluation of the Risk
The Committee recognizes that it is not possible to prove that any 
individual case was caused by the vaccines and that no laboratory tests 
available can provide a definitive answer. Nevertheless, considering 
the epidemiological evidence developed with respect to the total group 
of compatible cases, the Committee believes that at least some of these 
cases were caused by the vaccine.
The extent of the risk can be estimated from the incidence rates 
per million doses of the vaccine which have been distributed for use.
It was small and differed by type of vaccine and age. For Type III 
vaccine the over-all rate is 0.40 per million doses; for Type I, 0.16; 
and for Type II, .02. For trivalent vaccine the data available regard­
ing amounts of vaccine distributed are limited and the rate cannot be 
estimated.
In the age group under five, 6 cases followed Type III vaccine 
administration, giving an estimated rate of 0.53 per million doses; 2 
cases followed Type I vaccine for a rate of 0.17. In the 5-14 year age 
group the rates fcr both vaccines fell below 0.10. In older age groups, 
the rates are higher, particularly for Type III vaccine. In the age 
group from 20-39 it exceeds 0.50, or one case per 2,000,000 doses 
distributed.
From this evidence it was inferred that the risk is highest for 
Type III; the evidence of risk is less definite for Type I vaccine. For 
Type II vaccine the rate is so low as to suggest absence of risk.
The Committee recognized that many additional factors enter into 
the appraisal of the extent of the risk in various population groups.
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For example, the risk following Type III vaccine in adults is higher 
in males than females. Furthermore, unimmunized adults who have lived 
in rural areas and those from upper socioeconomic groups would appear 
to be at greater risk than those who have had more opportunity for prior 
exposure to naturally spreading polioviruses.
Conclusions
In view of these considerations the Committee agreed to the following:
1. The extent of the assessed risk is sufficiently low relative 
to the risk of naturally occurring illness in children to 
warrant continuation and intensification of the poliomyelitis 
immunization program throughout the nation, although with some 
changes in emphasis.
2. Primary emphasis should be given in all communities to the 
immunization of all infants during their first year of life.
All communities which have not already organized continuing 
programs for the effective immunization of their infants and 
preschool children in all socioeconomic groups are urged to 
do so.
(The success of such programs is requisite for 
attaining the goal of the elimination of paralytic 
poliomyelitis since it is primarily those younger 
children who serve to transmit the natural infection 
within the community.)
3. Communities which have not yet embarked upon mass immunization 
programs are encouraged to do so during the coming fall and 
winter (1964-65).
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(Such programs will be of value only if they 
succeed in reaching unimmunized persons, 
particularly preschool children, in lower 
socioeconomic areas. Before embarking on 
mass programs, all communities should develop 
definitive plans for continuing immunization 
programs to care for the new susceptibles born 
into or moving into the community.)
4. The age groups to be immunized in mass programs and the 
vaccine chosen for use should be determined locally. The 
vaccination of individuals over school age (about 18 years) 
should generally be recommended only in those situations
in which unusual exposure to poliomyelitis might be 
anticipated, such as epidemics, entry into military service, 
and travel to other countries.
5, Vaccination of children on entry to school should become a 
routine practice.
(It is recognized that the duration of immunity 
following oral vaccine has not yet been adequately 
measured, but it is also recognized that the 
occasion of entry to school provides an excellent 
opportunity to reinforce artificial immunity from 
earlier vaccination and to provide primary immuni­
zation for those who may have been missed.)
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6. The order of administration of the monovalent vaccines, 
previously given in the order of Types I, III, and II now 
should be altered so that Type II would be first administered. 
(From serological studies and epidemiological 
evidence, Type II infection appears to confer some 
heterologous immunity against Types I and III infection. 
Giving Type II vaccine first should theoretically further 
diminish the slight risks associated with the other 
vaccine types. Furthermore at the present time with 
poliomyelitis incidence rates at an all-time low and 
with epidemics rare, there is no longer an overriding 
need to give Type I vaccine first as was believed to 
be important in the past.)
Recommended Immunization Practices Using Oral Polio Vaccines
A. Primary Immunization
1. For Infants
Either monovalent or trivalent vaccines may be used 
for primary immunization. If monovalent vaccines 
are used the schedule should be:
Type II, at the time of the first DPT injection.
Type I, at the time of the second DPT injection.
Type III, at the time of the third DPT injection.
If trivalent vaccine is used it should be given at the 
time of the first and third DPT immunizations. In both 
instances a dose of trivalent vaccine at the end of the 
first year of life is recommended to complete the primary
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immunization series. The final dose in breast fed infants 
should be delayed until cessation of breast feeding.
(The Committee recognized that many pedia­
tricians may give DPT injections at monthly 
intervals and that therefore the present recommen­
dation may lead to the administration of Type I 
vaccine at less than the optimal interval (2 months) 
after Type II vaccine. The many administrative 
advantages of full coordination of oral polio 
vaccine with DPT immunization were felt to over­
ride this slight disadvantage. The Committee stresses 
the importance of the final dose of trivalent vaccine 
at one year of age as an essential part of the 
primary immunization schedule.
2. For All Others
If monovalent vaccines are used:
Type II.
Type I, not less than 8 weeks after Type II.
Type III, not less than 6 weeks after Type I.
If trivalent vaccine is used:
Two doses should be given with an 8-week interval 
between doses.
B. Recommendations Concerning Further Immunization Using Oral 
Polio Vaccines ~
Further immunization should be given:
1. At the time of entry into elementary school.
(A single dose of trivalent vaccine is indicated 
except for those who have had no previous vacci­
nation in whom a primary series should be given.)
2. To those at unusual risk such as persons resident in
epidemic areas, individuals who are traveling abroad and 
those entering the military services.
(Further recommendations regarding the desirability 
of additional immunizations must await the results 
of longer term studies and continuing surveillance.)
C. Recommendations Concerning Community Immunization Programs
Using Oral Polio Vaccines
1. Monovalent vaccines are preferred and should be 
administered in accordance with the following schedule:
Type II.
Type I, not less than 8 weeks after Type II.
Type III, not less than 6 weeks after Type I.
2. When circumstances exist which make the use of trivalent 
vaccine more desirable for the conduct of mass immuni­
zation programs, it is recommended that at least 8 weeks 
elapse between the first and second feedings.
D. Recommendations Concerning Specific Problems
1. The Committee knows of no data which would contraindicate 
use of oral polio vaccine during pregnancy per se.
2. With naturally occurring poliomyelitis at its present 
low level, the Committee sees no need to delay indicated 
tonsillectomies because of the season of the year,
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provided that the child has been adequately immunized. 
Recent oral vaccine administration also should not serve 
as a contraindication to needed tonsillectomy.
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SUBJECT: REPORT OF SPECIAL ADVISORY COMMITTEE ON ORAL POLIOMYELITIS
VACCINE TO THE SURGEON GENERAL OF THE PUBLIC HEALTH SERVICE 
(JULY 17-18, 1964)
Comments by Albert B. Sabin, M.D.
I would like first of all to emphasize those portions of the report 
with which I am in full agreement. These are:
1) That communities which have not yet had mass campaigns should have 
them during the forthcoming autumn and winter (1964-1965). The 
mere absence of cases £or several years in communities with large 
numbers of persons who have not had the benefit of immunization 
with oral poliovirus vaccine should constitute a warning of po­
tential future outbreaks rather than a basis for complacency.
2) That special emphasis be pla.ced on the immunization of infants 
during the first year of life. If this is not done on a larger 
scale than heretofore even communities that have already had 
satisfactory mass campaigns will not long continue to enjoy free­
dom from poliomyelitis.
3) That pending ultimate determination of the duration of immunity 
following oral vaccine, vaccination of all children on entry to 
elementary school should become a routine practice. In my opinion, 
they should have a single dose of trivalent vaccine if they have 
been previously immunized with oral vaccine and a full primary 
series if they have had no oral vaccine before.
The items in this report with which I disagree are concerned 
with the following:
1. Significance of the Very Small Number of Cases of Vaccine Associated 
Paralytic PiseasTI
It has been recognized by all (see Surgeon General's Report of 
September 20, 1962) that concurrent cases of paralytic disease must 
be expected in association with vaccination in non-epidemic areas, 
the expected number being lower than in epidemic areas but not zero. 
These concurrent cases could be expected to be composed of some that 
were caused by polioviruses in persons that were incubating the 
infection at the time they received the vaccine, some that clini­
cally simulated poliomyelitis, but were caused by a variety of 
factors including other naturally occurring viruses which could be 
displaced from the intestinal tract by the vaccine strains that were 
fed. There can also be justifiable differences of opinion among
2
competent persons regarding the clinical diagnosis as well as 
judgments of compatibility as was demonstrated in my analysis of 
the vaccine associated cases reported in 1962 (J.A.M.A., 183:268-271, 
1963). In this connection, it is noteworthy that of the 15 Type III 
1962 vaccine associated cases accepted as "compatible" by the majority 
of the present committee, there are 4, which on the same evidence, 
were not accepted as "compatible" by the majority of the 1962 Public 
Health Service committee and 5 that were eliminated on clinical 
grounds by the 1962 AMA committee. It is also noteworthy that 1 
of the 6 Type III, vaccine-associated cases regarded as polio-like 
and accepted as "compatible" in 1962 by all but one member of the 
PHS and AMA committees, after a lapse of more than a year developed 
further clinical manifestations that made the diagnosis of dissem­
inated myelitis acceptable to all, and thus was unanimously removed 
from the "compatible" group. I also take exception to the third 
criterion for "compatibility" which calls for "laboratory data not 
inconsistent with respect to multiplication of the vaccine virus 
fed.*' On the basis of this criterion, Type III cases have been 
accepted as "compatible" when there was no laboratory work (3 cases), 
when no virus was isolated (13 cases), when neutralization tests 
were either not done (7 cases) or were inadequate (9 cases), and 
even when the serologic data indicated a high probability that the 
vaccine virus did not multiply prior to the onset of illness (5 
cases).
Nevertheless, according to its own criteria for all vaccine associated 
cases from 1961 to 1964, the report comes up with the interesting 
finding that following the administration of approximately 100 
million doses of each of the 3 types of monovalent vaccine, only 
2 "compatible" cases were associated with Type II, 15 with Type I 
and 36 with Type III. While recognizing "that it is not possible 
to prove that any individual case was caused by the vaccines" the 
present report states that the above "epidemiologic" or "statistical" 
evidence is the basis for the belief "that at least some of these 
cases were caused by the vaccine" and proceeds to calculate the 
"extent of the risk1* on the basis that all of the so-called "com­
patible" vaccine-associated cases were caused by the vaccines - 
the conclusion being that the risk is "highest" for Type III with 
one "compatible" case per 2.5 million doses, "less definite" for 
Type I with one "compatible" case per 6.25 million doses, and 
"suggestively absent" for Type II with one "compatible" case per 
50 million doses.
The question therefore is whether one can properly take the one 
"compatible" case per 50 million doses of Type II vaccine as the 
baseline of expected concurrent incidence of polio-like paralytic 
disease and regard everything significantly above it as poliomyelitis 
caused by the vaccine viruses? In view of the very small numerators 
and extraordinarily large denominators and the well-known variability
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in the sporadic occurrence of poliomyelitis and other polio-like 
paralysis, is it not possible that under different circumstances 
the Type II vaccine virus might also be incriminated on the same 
type of "guilt by association" or "guilt by statistical probability"? 
Actually this appears to be the situation with the 4 "compatible" 
cases that have occurred after the relatively small amount of tri- 
valent vaccine that has been used thus far - Type II virus only 
having been recovered from 2 of these, Type I only from one and 
Type III only from one. If the committee is to adhere to its own 
criteria that the vaccine virus that is found in the stools should 
for purposes of evaluation be regarded as the agent responsible for 
the disease, 2 of the 4 trivalent vaccine "compatible" cases must 
be assigned to Type II. If we assume that only about 2 to 4 million 
doses of trivalent vaccine had been distributed up to May 1964 (and 
it is regrettable that commercial secrecy precludes more precise 
information), the occurrence of one Type II "compatible" case per 
1 or 2 million doses of trivalent vaccine compared with only 1 
"compatible" case per 50 million doses of monovalent Type II vaccine 
would constitute a highly significant statistical difference. If 
the committee had followed its own "epidemiologic" or "statistical" 
evaluation it should have concluded that the Type II vaccine virus 
may be responsible for some cases of paralytic disease when it is 
given in a trivalent mixture and not when it is given by itself.
My point is that the 1 in 50 million Type II yardstick adopted as 
a baseline for "epidemiologic" or "statistical" incrimination of 
Type I or Type III oral polio vaccines as a rare cause of vaccine 
associated paralytic disease is unrealistic and untenable. I
I believe that a separate analysis of the vaccine associated cases 
that occurred in 1963 and 1964 provides additional illuminating 
data, since, with the exception of about 2.8 million doses of 
Type I vaccine that were given during summer outbreaks in 1963, 
the remainder of the vaccine was used during the autumn, winter 
and spring. About 59 million doses of Type I, 54 million doses of 
Type II, and 76 million doses of Type III were distributed from 
January 1, 1963 through May 1964, and it is also evident that a 
considerable proportion of the 44 million doses of Type I, 39 
million doses of Type II and 23 million doses of Type III that 
were distributed in 1962 were actually used in 1963. It is note­
worthy, therefore, that by the committee's own criteria only 4 
"compatible" cases occurred among an estimated 60 million persons 
who received the Type I vaccine in 1963 and 1964. The somewhat 
larger number of Type III vaccine associated cases - 16 probable 
and 6 "possible" cases among an estimated 76 million in 1963 and 1964 - 
is particularly suspect because of the unusual distribution of these 
cases among the sexes. Naturally occurring poliomyelitis is slightly 
more prevalent among males than females; in 1960, among 2,218 paralytic
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cases in the U. S. A., 58% were in males and 42% in females of all 
ages - in the age group of 20 and over it was 59% in males and 
41% in females (See U.S.P.H.S. Poliomyelitis Surveillance Report 
No. 234 of August 18, 1961). However, among the total group of 
22 "compatible" cases (probable + "possible") following 76 million 
doses of Type III vaccine in 1963 and 1964 there was only one 
female - a 27-year old woman who had received 4 doses of Salk vaccine 
prior to receiving the oral vaccine. If the report were to apply 
the same kind of "epidemiologic" evaluation to these data, it 
should have concluded that the Type III vaccine is without risk 
for females of any ageT
Another reason why I cannot accept the conclusions of this report 
about Type III vaccine risk - and the role of age in that risk - is 
contained in the 1964 results which are again different from those 
in 1963. After an estimated distribution of about 22 million doses 
of Type III vaccine from January through May, 1964, there have been 
only 2 probable "compatible” cases - both of them under 1 year of 
age. The four "possible compatible" cases constitute a particularly 
dubious lot as regards evidence of infection with Type III virus 
prior to onset of illness. In two cases there was no Type III 
neutralizing antibody at 31 and 32 days respectively after ingestion 
of the vaccine; in the third case no virus was isolated from stools 
obtained 18 days after the vaccine and the serologic data provided 
no evidence that the Type III virus had multiplied; the fourth case 
was clinically atypical, had a history of having received 5 doses 
of Salk vaccine, and there were no laboratory data.
2. Statement that Vaccine Associated Cases Occurred Largely Among Adults.
Quite aside from the fact that many of the "compatible" cases in 
adults are clinically dubious, the statistical analysis of estimated 
rates based on the Bureau of Census Survey of September 1963 (see P.S.U. 
No. 284, April 20, 1964), shows no particular pattern other than the 
unpredictable distribution of small numbers. Actually if one takes 
only the major groups of under 20 years and 20-49, one finds for 
Type I slightly more under 20 (1 in about 5.7 million) than in 20-49 
(1 in about 9.5 million). For Type III, it is the reverse with 1 
in about 4.4 million under 20 and 1 in about 1.9 million in the 20-49 
group.
3. Statement that Unvaccinated Adults in Rural Areas and Upper Socio- 
Economic Groups Are at Greater Risk.
This is not borne out by an examination of the data on individual 
groups of "compatible" cases (e.g. Type III cases in 1963) for many 
of the "compatible" adult cases are in persons who have had 3 or 
more doses of Salk vaccine and absence of vaccination does not 
necessarily mean absence of naturally acquired antibody. Moreover, 
there is no evidence that the proportion of previously unvaccinated 
adults among the "compatible" cases is significantly greater than 
in the general population.
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4. Statement that in Mass Programs the Age Groups to be Immunized Should
be Determined Locally but that "the Vaccination of Individuals over* 
School Age CIS Years) should Generally Be Recommended Only in Those 
Situations in Which Unusual Exposure to Poliomyelitis Might be 
Anticipated..... "
On the basis of the data presented above there is no good reason 
for adults of either sex not to avail themselves of the simple and 
inexpensive opportunity to be immunized against poliomyelitis.
Although it is true that most adults do not need it because they 
are already naturally immune, there is no easy way of identifying 
those who are not immune. Paralytic polio is more severe and tragic 
in adults, and they should not rely on immunization by contact with 
vaccinated children or on the diminished circulation or elimination 
of paralytic polioviruses from their community following mass 
vaccination of the children.
5. Recommendation that the Order of Administration of the Monovalent 
Vaccines be Changed from the Present I, III, II to II, I, III.
The reason offered for this recommendation is that "giving Type II 
vaccine first should theoretically further diminish the slight risks 
associated with the other vaccine types." Examination of the avail­
able data for Type II neutralizing antibody on the Type III "compat­
ible" cases indicates that most of them had prior immunity to Type 
II virus. Moreover, the 1963 experience in California where the 
Type III vaccine was in most instances given after the Types I and 
II provides no support for this recommendation. California con­
tributed 5 of the 16 "compatible" Type III cases in 1963 - 3 of 
these in persons who had Types I and II vaccine before Type III and 
2 in persons who had Type III as the first dose. However, one of 
the two latter cases, a man aged 27 years, had previously had 5 
or 6 doses of Salk vaccine and had Type II neutralizing antibody, 
and the other (aged 18 months) had previously had 3 doses of Salk 
vaccine and had neither Type I nor Type II antibody.
Although there is no contraindication to giving the Type II vaccine 
first provided an interval of at least 8 weeks is allowed to elapse 
before the Type I is given, I would regard the following as objections
a) In primary immunization of children during the first months of 
life when DPT and oral polio vaccine are given simultaneously 
the frequent 1 month interval between the doses can be expected 
to interfere with adequate multiplication of the Type I virus 
in a significant proportion of children.
b) Taking into consideration those who may not return after their 
first dose as well as those who will miss getting their make-up 
dose of trivalent vaccine at 1 year of age (especially in
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clinics), the least effective procedure for providing immunity 
against the most prevalent Type I virus would thus be used.
c) The Public Health Service would be recommending switching to a 
procedure whose effectiveness in the first months of life has 
not been tested.
d) The recommendation for giving Type II first is inconsistent 
with the simultaneous recommendation of the use of trivalent 
vaccine, since in triple negative persons the latter usually 
results in the simultaneous multiplication of the Type II and 
III viruses.
6. Use of Trivalent Vaccine in Community Programs and for Routine Immu­
nization.
a) Although the statement is made that monovalent vaccines are 
preferred for community programs, it is also stated that when 
certain circumstances make the use of trivalent vaccine more 
desirable two doses are recommended. In my opinion, two 
doses of trivalent vaccine should not be recommended for 
community programs in the U. S. A. under any circumstances 
because intestinal resistance to reinfection, a prime objective 
in community programs, can be expected to be less effective 
after 2 doses of trivalent vaccine, and the antibody response 
for Type I is inadequate in a certain proportion of triple 
negative persons.
b) We have no data to show that the administration of two doses 
of trivalent vaccine to infants at about 2 months and 4 months 
of age (together with the first and third doses of DPT) 
followed by a third dose at the end of the first year of life - 
particularly when many children will receive some of these 
doses during the summer months - will provide adequate immuni­
zation for the maximum number of infants. The available data 
on the high effectiveness of two doses of trivalent vaccine at 
an interval of 8 weeks were obtained on 6 month-24 month old 
children during the winter months in a northern city. Until 
further data become available, I would regard it as advisable 
that when immunization is begun at about 2 months of age with 
trivalent vaccine that 3 doses be given at 2 month intervals
to be followed by a fourth dose at the end of the first year 
of life or later if breast feeding is still in progress.
c) While two doses of trivalent vaccine, 8 weeks apart, may be 
adequate for all persons over 1 year of age when these are given 
during the cold months of the year, I believe that a third
dose is desirable for children living in parts of the U. S. A. 
with subtropical climates as well as for those who may begin 
their primary immunization during the warm months of the year 
in northern climates.
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7. Lack of Positive Recommendation that Oral Polio Vaccine (OPV) is the 
Vaccine of Choice for Routine Immunization of Children?
Since the committee report has properly placed so much stress on 
the routine immunization of infants during the first year of life, 
it is regrettable that it has failed to bring to the attention of 
physicians and the public the demonstrated superiority of OPV over 
IPV (Salk vaccine) especially for immunization of the oncoming 
generations. It has been repeatedly shown that the antibody response 
of infants to IPV is of a low order and very often transitory. The 
recent demonstration of the very high effectiveness of even two doses 
of trivalent vaccine in producing antibodies among infants from the 
lowest socio-economic groups provides additional data for a positive 
recommendation. In addition to the above superiority in production 
of antibody there is the demonstrated high incidence of intestinal 
resistance which is most important for interfering with the circu­
lation of virulent polioviruses in the community. Although OPV is 
gradually being used more and more in routine pediatric immunization 
by private physicians and health departments, IPV is still begin used 
on a large scale for such purposes - to the detriment of achieving 
the optimum immunization of both the individual and the community.
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Since 1961 when the oral poliomyelitis vaccines were first made 
available for general use in the United States, scattered cases of 
paralytic disease have occurred in association with these vaccines.
Many of the cases have been clinically indistinguishable from 
poliomyelitis. Epidemiologically, the pattern of their occurrence 
has raised the possibility that some may have been caused by the 
vaccine.
In 1962 when the existence of this problem was first appreciated, 
the Surgeon General of the Public Health Service convened a Special 
Advisory Committee which met on a number of occasions between August 
and December. The Committee reviewed in detail reported cases of 
paralytic disease occurring within a period of 30 days following 
ingestion of the oral poliomyelitis vaccines. The Committee concluded 
that 18 cases of paralytic poliomyelitis were "compatible with the 
possibility of having been induced by the vaccine".^ Of these, 11 
followed Type III vaccine and 7 followed Type I vaccine. The Committee 
concluded that "the maximum potential risk for Types I and III vaccine 
is of the order of one per million or less overall; but higher for 
those over 30 years of age." The Committee recommended "that community 
plans for immunization be encouraged" but "because the need for immuni­
zation diminishes with advancing age and because potential risks of 
vaccine are believed by some to exist in adults, especially above the 
age of 30, vaccination should be used for adults only with the full 
recognition of its very small risk."
2
Following this report, additional community-wide programs employ­
ing oral poliomyelitis vaccines have been conducted in many parts of 
the country, especially in urban areas. By May 1964, about 100 million 
doses of each of the 3 types of vaccine had been distributed plus 
several million doses of oral trivalent vaccine. Additional cases of 
paralytic poliomyelitis associated with the administration of the oral 
vaccine have been reported. The total number of such reports received 
by the Public Health Service through June 1964 is 123. This number 
includes those cases reviewed by the Committee in 1962. Of this total,
36 cases occurred in epidemic areas where mass immunization programs 
were undertaken as emergency control measures. The remaining 87 cases 
were widely scattered and occurred in non-epidemic areas usually follow­
ing community-wide oral poliomyelitis vaccination programs.
Because of this continued incidence of vaccine associated cases, 
a Committee* was again convened by the Surgeon General to re-assess 
the problem and to develop recommendations for the future use of oral 
poliomyelitis vaccines. The Committee met on July 17-18, 1964.
The report of the Committee is published elsewhere in this issue.
The present paper summarizes the basic epidemiological information that 
was considered by the Committee in arriving at its conclusions and in 
making its recommendations.
* Members of the Committee are: Dr. Luther L. Terry, Surgeon General,
Chairman; Dr. James L. Goddard, Dr. Donald A. Henderson, Dr. Ernest A. 
Ager, Dr. Gordon C. Brown, Dr. Alice D. Chenoweth, Dr. Geoffrey Edsall, 
Dr. David T. Karzon, Dr. Theodore A. Montgomery, Dr. Roderick Murray, 
Dr. Paul F. Wehrle, Dr. David Bodian, Dr. John P. Fox, Dr. A. L. Gray, 
Dr. William McD. Hammon, Dr. Alexander D. Langmuir, Dr. Albert Sabin, 
and Dr. Edward B. Shaw.
3
Sources of Data and Classification of Cases
The Poliomyelitis Surveillance Unit of the Communicable Disease 
Center receives case reports from State and local health departments 
through the National Morbidity Reporting System. In addition, since 
1958, individual surveillance forms have been submitted for each case, 
a preliminary form which supplies basic epidemiologic data, and a follow­
up form which includes information regarding extent of residual paralysis 
of the case plus results obtained in laboratory studies. The incidence 
of cases of poliomyelitis with residual paralysis at 60 days represents 
the most reliable index presently available to assess, on a continuing 
basis, the national status of poliomyelitis.^
Since December, 1961, 123 cases of paralytic poliomyelitis have 
been reported which occurred less than 30 days after administration of 
the oral poliomyelitis vaccines. These were scrutinized with greater 
care. Detailed clinical and epidemiological information regarding these 
cases was obtained. Many were examined by special consultants. Virological 
and serological specimens were studied intensively.
Of the 123 vaccine associated cases, 36 occurred in epidemic areas 
in conjunction with emergency vaccine feeding programs. Most undoubtedly 
were in the incubation period of a naturally acquired infection at the 
time of feeding. The remaining 87 cases occurred in non-epidemic areas; 
they were widely scattered throughout the country. These latter cases 
received particular attention.
The Advisory Committee reviewed all available information pertain­
ing to each of the 87 vaccine associated cases which had occurred in
non-epidemic areas. The cases were classified into one of three 





The cases were classified as "compatible" if they met the follow­
ing criteria:
1. An onset of illness between 4 and 30 days following feeding 
of the specific vaccine type in question and with an onset 
of paralysis not sooner than 6 days after the feeding.
2. Significant residual lower motor neuron paralysis.
3. Laboratory data not inconsistent with respect to multi­
plication of the vaccine virus fed.
4. No evidence of: (a) upper motor neuron disease, (b)
definite sensory loss, or (c) progression or recurrence 
of paralytic illness one month or more after onset.
Cases not meeting these criteria were designated "excluded" with 
respect to the question of significant residual paralytic illness 
related to vaccine administration. Those for whom the data were 
considered insufficient upon which to base a judgment were placed in 
the category of "uncertain".
The "compatible" cases were further subdivided into "probable" and 
"possible" categories employing as guidelines for the "probable" cases:
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1. Evidence of fever at onset of paralysis.
2. History of systemic illness preceding the development of 
paralysis.
3. Clinical evidence of meningeal involvement manifested either 
by nuchal rigidity or cerebrospinal fluid cell count greater 
than 10 cells per cubic milliliter.
Cases in the "possible" category lacked one or more of these 
criteria, frequently for want of adequate observation at the time of 
the acute illness.
Poliomyelitis Incidence
Progress in the control of poliomyelitis in the United States is 
depicted in Figure 1. The decline in annual incidence during the past 
10 year period has been marked. The average annual rate for paralytic 
cases for the period 1950-54 was 14.6 per 100,000 population, compared 
with an average rate of 0.4 for the 3 year period 1961-63. The 
occurrence of poliomyelitis by four-week periods since 1961 is shown 
in Figure 2 on a greatly expanded scale. The absence even of a seasonal 
summer rise in incidence in 1964 is notable.
Throughout this recent period there were no epidemics comparable in 
size to many observed in past years. The largest outbreak since 1962 
occurred in Texas and involved a number of different communities in 
many parts of the State; 174 cases were reported. The location and 
extent of the outbreaks of poliomyelitis in the country during 1962 and 
1963 is portrayed in Figures 3 and 4 and in Table 1. "Epidemic areas" 
are defined as those areas reporting 6 or more paralytic cases of
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which at least 4 occurred within a 30-day period. During the past two 
years, a total of 16 outbreaks in 13 States were recorded. All were 
caused by Type I poliovirus. In 13 of these 16 outbreaks, mass immuni­
zation programs were conducted in an effort to abort the epidemics. No 
outbreaks have been observed during the first 8 months of 1964.
The epidemic areas in 1962 accounted for 304 of the 691 reported 
cases with residual paralysis. In 1963, 137 of the 331 cases occurred 
in epidemic areas (Table 2). In both epidemic and non-epidemic areas, 
cases were predominantly in the younger age groups, approximately half 
being under 5 years of age. A somewhat higher proportion of adult cases 
was recorded in non-epidemic areas.
As shown in Table 3, Type I poliovirus was the most prevalent type 
in both epidemic and non-epidemic areas. All outbreaks were due to 
Type I infection, although in 1962, 24 scattered Type III cases were 
also identified in these areas. In the non-epidemic areas, Type III 
accounted for approximately 35 percent of the laboratory confirmed cases 
in 1962 and 30 percent in 1963. In the first half of 1964, Type III 
poliovirus accounted for 11 of the 22 isolates.
Vaccine Associated Cases
Of the 123 cases of paralytic poliomyelitis occurring less than 
30 days after oral vaccine administration, 87 were reported from non­
epidemic areas, 36 from epidemic areas.
Non-epidemic Areas: Of the 87 non-epidemic area cases, the Advisory
Committee categorized 57 as being "compatible" with vaccine-induced 
disease (Table 4). Fifteen followed Type I vaccine, 2 followed Type II,
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36 followed Type III and 4 followed trivalent vaccine. There were 9 
cases classified as "uncertain” and 21 cases were placed in the "excluded" 
category.
All of the 57 "compatible" cases had significant residual paralysis, 
this being a basic requirement for classification as a "compatible" case. 
There were 2 deaths, one followed Type III vaccine and one trivalent 
vaccine administration. Histological examination revealed acute anterior 
horn cell disease in both, although the immediate cause of death in one 
was considered to be the result of a pulmonary embolus.
The 57 "compatible" cases were reported from 49 counties in 24 
States; 41 of the cases represented the only cases reported from their 
respective counties during the past two and one half years. A small 
concentration of "compatible" cases were observed in the San Francisco 
Bay area, 5 cases resident in 4 counties occurred between October 1 and 
November 6, 1962, less than 30 days after a Type I community vaccine 
program. In these counties during 1962, 6 other cases of poliomyelitis 
were reported.
In Nebraska, 8 cases occurred in 7 different counties between July 1 
and September 3, 1962, less than 30 days following the administration of 
Type III oral vaccine. Except for vaccine associated cases, no other 
poliomyelitis cases were reported in Nebraska during 1962. An intensive 
State-wide search for possible non-vaccine related cases revealed a 
number of records of aseptic meningitis, infectious polyneuritis and 
other neurological diseases but no additional cases of paralytic 
poliomyelitis.^
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In North Carolina, 3 cases among residents in 3 separate counties, 
occurred between March 7 and April 7, 1964, within 30 days after tri- 
valent vaccine ingestion. One other case of poliomyelitis was reported 
in North Carolina during the first 6 months of 1964.
Intensive laboratory studies were conducted on many of these 
"compatible" cases. Polioviruses were isolated from a high proportion; 
in essentially all instances the type of virus identified was the same 
as the type last fed prior to onset of illness. Because of recent vaccine 
ingestion the diagnostic significance of the isolates was problematic 
except to indicate that proliferation of the vaccine virus had taken 
place. In many cases intensive studies were conducted in an effort to 
identify a possible infection with certain of the enteroviruses or other 
pathogens such as arboviruses that may sometimes cause paralytic illnesses. 
In none of the "compatible" cases did these suggest a diagnosis other 
than poliomyelitis.
The vaccine administered to the "compatible" cases was provided 
by several manufacturers and involved many different production batches 
and filling lots. In each of the 3 geographic clusters, two or more 
lots of vaccine were involved and in 2 of the clusters, vaccine from 
2 or more manufacturers was given to "compatible" cases.
The history of previous immunization of the "compatible" cases with 
inactivated poliomyelitis vaccine is summarized in Table 5. Two-thirds 
of the cases had received no inactivated vaccine. Ten had received 
four or more injections.
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Epidemic Areas; Thirty-six cases of paralytic poliomyelitis were 
reported from epidemic areas which occurred less than 30 days after 
oral vaccine administration. Since these cases occurred in areas where 
naturally occurring strains were demonstrably present and since many of 
the cases undoubtedly were incubating these strains at the time of 
feeding, the Advisory Committee did not attempt to appraise this group 
of cases with respect to "compatibility" with vaccine induced disease. 
Surveillance data did indicate that all of these cases had residual 
paralysis 60 days after onset of infection.
Of the 36 cases, 34 followed administration of Type I vaccine and 
2 followed administration of Type III vaccine. The vaccine associated 
epidemic area cases occurred during eight of the outbreaks noted in 
Table 1. As previously noted, all recent outbreaks in this country have 
been caused by Type I poliovirus; Type I oral polio vaccine has been 
employed as a control measure. Thus, the occurrence of vaccine associated 
cases with types other than Type I would be exceptional. The two cases 
which occurred following Type III vaccine administration were reported 
from Texas during the epidemic period; both were adults.
Contrast of Epidemiological Patterns: The age and sex distributions
of the "compatible" and epidemic area vaccine associated cases are 
compared in Table 6. "Compatible" cases are sharply concentrated among 
adults; 44 or 77 percent are 15 years of age and older; of the epidemic 
area cases, only 6 or 17 percent are 15 years or older. Of the 57 
"compatible" cases, 46 or 80 percent are males, whereas the two sexes 
are represented equally among the epidemic area cases.
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The intervals from dates of vaccine administration to dates of 
onset of first symptoms are presented in Figure 5. The epidemic area 
cases tend to occur soon after vaccine ingestion; 27 of the 36 cases 
occurred less than 12 days after vaccination. The 9 cases with intervals 
greater than 12 days occurred in Texas during the 1962 epidemic. Included 
in this group are the 2 Type III cases previously mentioned.
The intervals following vaccine administration among the 
"compatible" cases tend to fall in the period, 7 to 21 days. 
Parenthetically, however, it should be noted that the criteria for 
designating a case to be "compatible" required that at least four days 
must have elapsed between vaccine feeding and onset of illness. Among 
the 21 cases reviewed by the Committee which were not placed in the 
"compatible" category, there were two cases with intervals between 
administration of vaccine and onset of illness of between 0 and 3 days. 
Relative Frequency of "Compatible" Cases: The incidence of "compatible"
and total cases in children and adults by quarter-year periods from 
January 1962 to June 1964 is shown in Table 7. Although there has been 
a marked decline in the incidence of total cases over this time span, 
the frequency of "compatible" cases has not declined proportionately.
Among children the relative frequency of "compatible" cases to the 
total was about 2 percent in 1962 and 1963. This rose somewhat during 
the first half of 1964, although because of the small numbers of cases 
involved, this increase may not be significant. Among the adults in 
1962, 19 percent of the total cases were "compatible". In 1963, this 
proportion rose to 33 percent, and in 1964, 10 of 14 cases or 71 percent 
were "compatible".
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Use of the Vaccine
Complete records of vaccine utilization in the nation are not 
available but reasonable estimates may be made from data supplied by 
the commercial firms to the Biologies Surveillance Unit, CDC, regarding 
vaccine distribution. These data are presented in Table 8.
Since licensure of the monovalent vaccines through May 1964, 104 
million doses of Type I have been distributed; 93 million doses of 
Type II and 99 million doses of Type III. In addition, several million 
doses of trivalent vaccine have been utilized recently, predominantly 
in physicians' offices and to a limited extent in community programs.
The greatest use of the monovalent vaccines has been in community 
immunization programs. Most such programs included all age groups 
in the community; a few were limited to younger children.
Of the total amount of vaccine distributed, a proportion of the 
vaccine would not have been administered because of normal vaccine 
"wastage". In a number of community programs "wastage" represented 
as much as 15 to 30 percent of the available supply. Overall, it is 
estimated that at least 10 percent of vaccine distributed was not 
actually administered because of this "wastage" factor.
The proportionate distribution of vaccine by age group can be 
approximated from two sources of data. In September 1963, through 
the random sample survey of 35,000 households conducted by the Bureau 
of the Census, a question regarding the number of doses of oral vaccine 
received was asked of all individuals up to 50 years of age. For those 
over 50, an estimate of participation can be derived from data available
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from community vaccination programs. While different programs varied 
in the extent of their coverage, surveys throughout the nation revealed 
that all age groups, particularly the adults, responded remarkably well.
Based on the data of vaccine distribution and the proportionate 
distribution of vaccine by age, an estimate has been made of the total 
amounts of Type I and III vaccine administered through May 1964, by age, 
in non-epidemic areas (Table 9). Relating the "compatible" cases to 
these estimates, the extent of the risk has been estimated per million 
doses of vaccine administered.
The overall rate for Type I vaccine is 0.17 per million doses 
fed; for Type II, 0.02; for Type III, 0.40. The rates vary quite 
markedly by age. In the age group under five, 6 cases followed 
Type III vaccine giving an estimated rate of 0.53 per million doses;
2 cases followed Type I in this age group for a rate of 0.19. In the 
5 to 14 year age group, the rates for both vaccines are below 0.10.
In the older age groups, the rates are higher, particularly for 
Type III vaccine; among those 15 to 39, the rate is 0.64 per million 
doses fed or one case per 1.6 million doses administered.
Cases Among Household Contacts
Throughout the period since first licensure of oral poliomyelitis 
vaccine, a careful surveillance has been maintained for cases of polio­
myelitis developing among unvaccinated household contacts. The 
frequency of such cases has been low. Two contact cases, one in an 
18 month old child, the other in a 29 year old male, have been reported 
within 30 days after primary vaccine administration. Both were household
contacts of Type III vaccinees. An additional case occurred in a 6 
month old child, who was known to have been in close association with 
other children who were fed Type III vaccine.
Discussion and Summary:
In the United States the incidence of paralytic poliomyelitis has 
declined precipitously in recent years. The number of cases recorded 
during 1963 was 331, only 48 percent of the total in 1962, which was 
itself a record low year. In 1964, through June, reported cases were 
less than half as frequent as in 1963. Epidemics of poliomyelitis as 
previously known have disappeared; outbreaks have become infrequent 
and localized.
A cause for concern, however, has been the continuing occurrence 
of cases of paralytic disease in association with the administration of 
the oral poliomyelitis vaccines. Reported since December 1961 have been 
123 vaccine associated cases. The epidemiological characteristics of 
36 of these cases, which occurred in conjunction with vaccine control 
programs in epidemic areas, were such as to suggest that most were in 
the incubation period of a naturally acquired infection at the time of 
feeding.
The 87 vaccine associated cases from non-epidemic areas were of 
greater concern and were scrutinized more carefully. Fifty-seven were 
adjudged by the Committee to be clinically indistinguishable from 
paralytic poliomyelitis; all had significant residual paralysis; their 
onsets occurred between 4 and 30 days after feeding and laboratory data
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were not inconsistent with respect to multiplication of the vaccine fed. 
These cases differed significantly in their epidemiologic characteristics 
from those in epidemic areas. The cases were widely scattered throughout 
the country and in most instances were the only cases of poliomyelitis 
to be reported in their respective counties. The interval from vaccine 
ingestion to onset of illness peaked in the range of 7 to 21 days.
The Advisory Committee concluded "that it is not possible to prove 
that any individual case was caused by the vaccines and that no laboratory 
tests available can provide a definitive answer. Nevertheless, consider­
ing the epidemiological evidence developed with respect to the total group 
of compatible cases, the Committee believes that at least some of these 
cases were caused by the vaccine."
The extent of the risk associated with the separate monovalent 
vaccine types was notably different. The rate per million doses fed 
was 0.40 for Type III and 0.02 for Type II; Type I was intermediate 
between these with a rate of 0.17 per million doses administered. Kith 
respect to Type III vaccine, the risk was significantly greater among 
adults than among children; for Type I vaccine, there were no 
appreciable differences by age.
Further definition of the risk in various population groups was 
not possible although certain groups did appear to be at greater risk 
than others. For example, the number of cases following Type III 
vaccine in adults was considerably higher among males than females.
In recent years, naturally occurring infections among adult males have 
become proportionately more frequent rising from less than 50 percent
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of the adult cases in 1 9 5 5 ^  to over 60 percent recorded during the
( 6)past three years. The immunization status of adult males with
respect to inactivated vaccine has been demonstrably poorer than for 
f 71that for females. Further, their opportunity for exposure to young 
children and, thereby, natural infection is less. They thus would 
appear to constitute a more susceptible group. Other susceptible groups 
would be those residing in rural areas and those from upper socioeconomic 
groups who have less opportunity for exposure to naturally spreading 
polioviruses. Although it was not possible to quantitate the relative 
frequency of vaccine associated cases among such groups, there did 
appear to be a higher frequency of occurrence of vaccine associated 
cases among those residing in the more rural areas and those in the 
upper socioeconomic groups.
Particularly notable is the increasing rarity of naturally 
occurring paralytic poliomyelitis among adults. In 1963, of 42 cases 
among persons 15 years and over, only 28 represented non-vaccine 
associated cases; during the first 6 months of 1964, only 4 cases of 
a reported 14 cases of paralytic poliomyelitis in this age group were 
non-vaccine associated.
Despite the administration of large amounts of vaccine in 
community programs, some of which included children only, vaccine 
associated cases among contacts have been infrequent. Prior to 
general vaccine use, concern was expressed that there might be mutant 
strains transmitted from vaccinees to non-vaccinees which would induce 
disease in the contacts.^ This has not proved to be a significant
problem.
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With these considerations in mind, the Advisory Committee 
recommended "changes in emphasis" of the national poliomyelitis program 
stressing continuing intensive immunization of infants and preschool 
age children, the groups demonstrably at greatest risk of naturally 
acquired infection and the principal disseminators of the natural 
infection within the community.
Table 1













Washington County, Arkansas 6 55,797 37,000
Los Angeles County, California 38 6,038,771 2,801,000
Cook County, Illinois 40 5,129,725 None
Northeast Kentucky 12 110,745 15,000
(Includes Boyd, Fleming,
Greenup, and Mason Counties)
Northeast Oklahoma 14 503,117 150,000
(Includes Creek, McIntosh, 
Muskogee, Tulsa, and 
Washington Counties)
Texas (Entire State) 174** 9,579,677 3,600,000
Fayette County, West Virginia 10 61,731 None
1963
Northwest Alabama 21 115,407 80,000
(Includes Lawrence, Winston 
Marion and Walker Counties) 
Duval County, Florida 24 455,411 420,000
Lowndes County, Georgia 7 49,270 None
Kent County, Michigan 6 363,187 348,000
Metropolitan Philadelphia, Pa. 43 4,342,897 1,500,000
(Includes Philadelphia, Chester, 
Delaware, Bucks and Montgomery 
Counties, Pa.; Burlington, Camden 
and Gloucester Counties, N.J.) 
Luzerne County, Pennsylvania 8 346,972 275,000
Cumberland and Perry Counties, Pennsylvania 15 151,398 77,000
Petersburg, Virginia 13 113,650 103,000
* Areas with 6 or more paralytic cases; at least 4 occurring within a 30-day 
period.
** Includes 2 California cases imported from Texas.
Table 2
Reported Cases of Poliomyelitis With 
Residual Paralysis in the United States 
Age by Epidemic and Non-Epidemic Areas 




Group Areas Areas Total
0-4 176 165 341
5-9 65 75 140
10-14 24 48 72
15-19 8 18 26
20-29 15 36 51
30-39 11 27 38
40+ 5 18 23




Number of Cases 
Epidemic Non-Epidemic 
Areas Areas Total
0-4 72 94 166
5-9 25 35 60
10-14 18 20 38
15-19 5 10 15
20-29 9 16 25
30-39 5 14 19
40+ 3 5 8














5-9 - 3 3
10-14 - 3 3
15-19 - 3 3
20-29 - 1 1




TOTAL _ 35 35
Includes two cases unofficially reported (4 and 39 years of age).
1964 cases reported through August 15 with onsets through June 27, 1964.
Table 3
Poliovirus Types Isolated in Epidemic and Non-Epidemic Areas 
From Cases of Poliomyelitis With Residual Paralysis 
1962, 1963 (Through June)
Epidemic Areas Non-Epidemic Areas
Poliovirus Poliovirus
Total Total Isolated Total Total Isolated
Year Cases Spec. T m Cases Spec. n_ III
1962 304 200 166 0 24 387 272 136* 8 76*
1963 137 104 93 0 0 194 134 66 5 31
1964** 0 . . . 35 28 9 2 11
* Includes double isolation of types I and III from two individuals.
** 1964 cases include those reported through August 15 with onsets
through June 27, 1964.
Table 4
Paralytic Poliomyelitis Occurring in Association 
With Oral Poliomyelitis Vaccines in Non-Epidemic Areas 
Categorizations by Advisory Committee With Respect To 
Vaccine Relationship; December 1961 - June 1964
Type Vaccine Categorization by Advisory Committee
Administered Year Compatible Uncertain Excluded
Type I 1961 2 (2) 0 0
1962 9 (7) 4 5
1963 2 (2) 0 3
1964 2 (2) 0 0
Total 15 (13) 4 8
Type II 1962 1 (1 ) 0 5
1963 0 0 0
1964 1 (0) 0 0
Total 2 (1 ) 0 5
Type III 1962 15 (11) 1 8
1963 16 (13) 2 0
1964 5 ( 2) 2 0
Total 36 (26) 5 8
Trivalent 1964 4 (2) 0 0
Grand Total 57 (42) 9 21
Table 5
Compatible Cases* by Broad Age Group and IPV Status 
December 1961 - June 1964
Age Doses of Inactivated Poliomyelitis Vaccine
OPV Group b 3 4+ Uliiv I Total'
I <15 0 1 1 2 0 4
15+ 7 1 0 1 2 1 1
II <15 0 0 1 0 0 1
15+ 1 0 0 0 0 1
III <15 4 0 3 1 0 8
15+ 19 0 0 6 3 28
Tri. <15 0 0 0 0 0 0
15+ 4 0 0 0 0 4
Total <15 4 1 5 3 0 13
15+ 31 1 0 7 5 44
Total 35 2 5 10 5 57
* Cases considered compatible by Advisory Committee
Table 6
Age and Sex Distribution of Vaccine 
Associated Cases of Poliomyelitis; 
"Compatible” Cases in Non-Epidemic Areas and 
Cases with Residual Paralysis in Epidemic Areas 
December 1961 - June 1964
Age "Compatible" Cases Epidemic Area Cases
Group M F Total M F Total
0-4 6 2 8 10 1 1 2 1
5-9 2 1 3 3 3 6
10-14 0 2 2 2 1 3
15-19 7 1 8 0 0 0
20-29 6 1 7 1 1 2
30-39 1 2 1 13 2 0 2
40-49 7 1 8 1 1 2
50+ _6 _ 2 _8 __0 _0 _0
Total 46 1 1 57 19 17 36
Table 7
Reported Cases of Poliomyelitis With 
Residual Paralysis and Vaccine Associated 
Paralytic Poliomyelitis Categorized as "Compatible"* 
By Quarter-Year Period and Broad Age Group 
Non-Epidemic Areas 
January, 1962 - June, 1964
Weeks** Under 15 Years 15+ Years
of Total ‘'Compatible" Percent Total ‘'Compatible" Percent
Year Onset Cases Cases "Compatible" Cases Cases "Compatible"
1962: 1-13 21 1 8 0
14-26 34 0 15 4
27-39 160 2 54 10
40-52 59 3 21 5
TOTAL 274 6 2.2% 98 19 19.4%
1963: 1-13 18 1 10 6
14-26 24*** 2 1 2 *** 5
27-39 81 0 13 0
40-52 24 1 7 3
TOTAL 147 4 2.7% 42 14 33.3%
1964: 1-13 6 1 10 6
14-26 15 1 4 4
TOTAL 21 2 9.5% 14 10 71.4%
* Categorized "compatible" by Special Advisory Committee.
** Does not include 20 cases with unknown onset.
*** Includes a "compatible" case not yet officially reported.
Table 8
Estimated Annual Distribution of Oral Poliomyelitis Vaccine* 
From Date of Licensure Through May, 1964 
(Thousands of Doses)
Type I Type II Tyr)e III
Year Annual Cumulative Annual Cumulative Annual Cumulative
Licensure: August 17, 1961 October 6 , 1961 March 27, 1962
1961 587 587 151 151
1962 44,568 45,155 39,379 39,530 22,687 22,687
1963 38,731 83,886 34,227 73,757 54,206 76,893
1964** 2 0 , 1 0 1 103,987 19,696 93,453 21,945 98,838
* Sources of Distribution Data:
January 1960-June 1962: State Health Departments and PHS Regional Offices 
July 1962-May 1964 : Biologic Surveillance Unit, CDC
** Through May
Note: All figures should be considered estimates.
Table 9
Estimated Incidence Rates by Age Group 
"Compatible" Cases Associated With Oral Vaccine Administration
Proportion . oEstimated 3Number Cases
Age of Vaccine Vaccine Received "Compatible" Per
Group Received (0 0 0's of doses) Cases Million Doses
Type I
0-4 12.63 10,719 2 0.19
5-9 16.36 13,885 1
10-14 14.66 12,442 1 U • Uo
15-19 9.98 8,470 4
20-29 11.79 10,006 1 0.24
30-39 13.25 11,245 2
40-49 11.33 9,616 1
50 + 1 0 . 0 0 8,487 3 0 . 2 2
Total 1 0 0 . 0 0 84,870 15 0.17
Type III
0-4 12.63 11,235 6 0.53
5-9 16.36 14,553 1
10-14 14.66 13,041 1 0.07
15-19 9.98 8,878 4
20-29 11.79 10,488 6 0.64
30-39 13.25 11,786 10
40-49 11.33 10,078 3 0 4250 + 1 0 . 0 0 8,895 5
Total 1 0 0 . 0 0 88,954 36 0.40
*Based on Bureau of Census Survey, September, 1963 (See PSU #284, April 20, 1964).
Vaccine status queried for individuals 0-49 years of age. Minimum estimate for
50+ age group based on selected community-wide programs for■ which survey or complete
tabulations were known for the 50+ age group.
2Estimates of total use derived by deducting 10 percent as "wastage" estimate from
total vaccine distributed in non-epidemic areas; (Type I: 9,6 8 6 ,0 0 0 doses) from
date of licensure through May 1964.
^Categorization made by Special Advisory Committee.»
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ANNUAL P O L IO M Y E L IT IS  INCIDENCE RATES  
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PARALYTIC POLIOMYELITIS REPORTED  
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Figure III
OUTBREAKS OF PARALYTIC POLIOMYELITIS
S O U R C E :  P O L I O M Y E L I T I S  S U R V E I L L A N C E  R E P O R T S
Figure IV
OUTBREAKS OF PARALYTIC POLIOMYELITIS












PARALYTIC P O LIO M Y E LIT IS  
OCCURRING WITHIN 30 DAYS OF OPV
INTERVAL BETWEEN VACCINATION AND ONSET 
December I, 1961 through June 27, 1964
RECEIVED
N O N -E P ID E M IC  AREAS *
Intervals by 3 -D a y  Periods
* Cases considered compatible by committee
Paralytic Poliomyelitis Cases (Non-Epidemic Areas) 
With Onsets Less than 30 Days After Receiving OPV
I. Cases Adjudged "Compatible" by Special Advisory Committee
A. Cases Following Type I










N. Y. Chautauqua 23 mo. F 12-16 4 I 7 3
N. Y. Chautauqua 56 M 12-28 0 I 28 Neg. 4
1962
Calif. Santa Clara 42 M 1 0 - 1 0 I 8 I 4
Calif. Alameda 32 M 1 0 - 1 0 I 7 I 3
Calif. San Francisco 2 F 1 0 - 1 1 2 I 18 I 3
Calif. Santa Clara 58 M 10-18 0 I 25 I 3
Calif. San Mateo 7 F 10-24 6 I 22 II** 2
Calif. San Diego 35 M 1 1 - 6 0 I 9 I 3
1 1 1 . Stephenson 16 M 10-4 Unk I 4 I 3
Iowa Story 14 F 10-14 3 I 9 I 3
Tenn. Gibson 25 M 8-30 1 I 10 I 3
1963
Wash. Yakima 61 F 3-14 0 I 1 1 I 2
Wise. Chippewa 18 M 3-26 Unk I 10 I 3
1964
Gel • Bartow 15 M 3-5 5 I 25 Neg. 3
Md. Pr. Georges 15 M 5-9 0 I 20 I 3
B. Cases Following Type II
1962
Ariz. Maricopa 6 M 3-9 3 II 1 2 3
1964
N. C. Lenoir 49 M 6-14 0 II 28
C. Cases Following Type III
State County Age Sex Onset
Mich. Branch 23 M 7-15
Mich. Midland 36 F 7-20
Neb. Douglas 18 F 7-1
Neb. Douglas 51 M 7-16
Neb. Dodge 37 M 7-23
Neb. Lancaster 6 M 8-5 or 1
Neb. Cherry 55 M 8-15
Neb. Phelps 50 F 8-16
Neb. Lincoln 57 M 8-24
Neb. Keya Paha 13 F 9-3
Ohio Portage 16 M 6-8
Ohio Cuyahoga 36 M 7-18
Okla. Logan 33 M 8-7
Oreg. Washington 48 F 5-5
Oreg. Benton 52 M 6-26
Calif. Sacramento 39 M 1-24
Calif. Los Angeles 30 M 3-1
Calif. Napa 39 M 3-23
Calif. Shasta 1 1 / 2 M 3-26
Calif. Los Angeles 27 M 1 2 - 1 0
Mass. Middlesex 2 1 M 5-28
Mass. Middlesex 27 F 6-7
Minn. Hennepin 19 M 5-27
Pa. Schuykill 30 M 6-8
Pa. Del aware 39 M 1 1 - 2 1
Pa. Delaware 47 M 1 1 - 2 1
S. C. Spartanburg 3 M 12-18
Tenn. Montgomery 1 1  mo. M 6-16
Texas Bexar 20 M 1-25
Idaho(NOR) 39 M 4-12





























































III 1 2 III
III 26 III
III c.9 III
C. Cases Following Type III
Doses
State County Age Sex Onset IPV
1964
Ala. Escambia 18 M 1-26 0
Ala. Escambia 28 M 3-28 0
1 1 1 . Adams 3 mo. M 1-28 0
Neb. Lancaster 41 M 3-14 5
Ohio Lucas 8 mo. M c.4/3 0
D. Cases Following Trivalent
1964
N. Y. Nassau 37 M 4-27 0
N. C. Alamance 43 M 3-16 0
N. C. Forsyth 43 M 3-9 0
N. C. Mecklenburg 48 M 4-7 0
II. Cases Adjudged ’’Inconclusive" by Special Advisory Committee 
A. Cases Following Type I
1962
Calif. Alameda 1 1 M 9-27 4
Calif.(NOR) Los Angeles 33 M 1 1 - 6 0
La. Allen 1 1 M 1 1 - 2 2 4
Mass. Hampden 1 1 M 7-22 4
B. Cases Following Type III
1962
N. Y. Onondaga 49 M 6-18 0
1963




OPV to Onset Isol.
60-Day* 
Status
III 2 1 Ill 3
III 20 III 3
III 1 1 III 2
III 5 - 3
III c . 1 0 Ill 3
Tri. 8 II 3
Tri. 15 I 5
Tri. 8 II 4
Tri. 16 III 3
I 4 Neg. 3
I 9 Neg. -
I 18 I 3
I 30 Neg. 4
III 26 Neg. 3
III 22-29 (?) - 3
B. Cases Following Type III
Doses
State County Age Sex Onset IPV
1963 (Cont’d.)
Wis. LaCrosse 38 F 5-4 3
1964
N. J. Mercer 35 M 2 - 1 0
N. J. Morris 41 F 3-23 4
III. Cases Adjudged "Excluded" by Special Advisory Committee 
A. Cases Following Type I
1962
Calif. San Benito 8 M 9-27 4
Calif. Marin 30 M 10-7 3
Mass. Bristol 7 M 6-15 5
Mont. Park 39 F 10-16 3
N. Y. Nassau 3 M 5-29 2
Idaho Ada 47 M 3-12 0
La. Evangeline 10 M 2-14 0
La. Rapides 4 M 4-14 5
I. Cases Following Type II
1962
Neb. Douglas 5 F 1 0 - 1 4
Ohio Mahoning 2 F 2-23 2
Ohio Cuyahoga 67 M 7-28 0
Ohio Huron 71 M 10-24 0
Texas Dallas 7 F 1 1 - 2 1  (?) 
12-24 (?)
4
Type Interval (Days) 60-Day
Fed OPV to Onset Isol. Status
III 13 Neg. 3
III 13 Neg. 3
III 22 Neg. 2
I 4 I 4
I 14 III 2
I 27 I 2
I 9 - 2
I 23 I 1
I 2 I 4
I 4 I 2
I 7 I 3
II 15 Cox. A-10 1
II 8 III 3




 to to to
 (N
C. Cases Following Type III
Stats County Age Sex Onset
Mass. Norfolk 4 M 7-2
Mass. Suffolk 54 F 7-5
Neb. Buffalo 46 M 8-20
Neb. Lancaster 10 M 8-9
Oreg. Multnomah 39 M 5-21
Oreg. Multnomah 6 M 5-25
Pa. Venango 4 M 6-6
Wash. Franklin 6 M 6 - 1 2
Doses Type Interval (Days) 60-Day
IPV Fed OPV to Onset I sol. Status
4 III 26 - 2
0 III 22 - 3
0 III 28 - 3
3 III 18 - 3
0 III 23 Ill 4
0 III 27 III 2
5 III 8 III 1
I 54 I
4 III 5 I 1
* Clinical Status at 60 Days:
1 - Complete recovery
2 - Minor involvement
3 - Significant disability
4 - Severe disability
5 - Fatal
** Specimen taken 2 days after receiving Type II vaccine
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